A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

Clinical trial NCT03563599 · COMPLETED

Trial details

NCT number: NCT03563599
Sponsor: Qurient Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB

Start date: 2018-07-23
Primary completion: 2019-09-09
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.